Unknown PHASE2 INTERVENTIONAL 4-arm NCT02525822

Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac® (Tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris

Sponsor: Valeant Pharmaceuticals

Conditions Acne Vulgaris

Interventions IDP-123 Lotion Tazorac Cream, 0.1%, Vehicle Cream Vehicle Lotion

Updated 7 times since 2017 Last updated: Sep 11, 2015 Started: Sep 30, 2015 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02525822, this PHASE2 trial focuses on Acne Vulgaris and remains ongoing. Sponsored by Valeant Pharmaceuticals, it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Oct 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Feb 2017 — Oct 2017 [monthly]

Not Yet Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE2

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Valeant Pharmaceuticals

Data source: Valeant Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.